Brazil 🇧🇷🇧🇷🇧🇷 being truly represented in #ASCO25! Bruna Pellini, MD and Ticiana Leal rocking the house!

Uromigos #ASCO25 Unsung Hero Award for RCC. lisaderosa and Laurence Albiges with a novel prospective trial of microbiome supplementation +Ipi/Nivo. Evidence of pharmacodynamic effects and encouraging initial clinical data.

Impact de la supplémentation orale en Akkermansia muciniphila dans le cancer du rein (RCC) , essai ev2101 Présenté par Dr lisaderosa Gustave Roussy

Hot topic! Marc Machaalani fantastic IM applicant this upcoming cycle presents data on KIM-1 in JR101 #ASCO25 OncoAlert

A topic that comes up during every discussion in the RCC biomarker space Check out Clara Steiner 's awesome work at 📍338 #ASCO25 OncoAlert

Happy to share that our study on gut microbiome associations with colorectal cancer (CRC) is out in Nature Medicine! (doi.org/10.1038/s41591…).

4 pictures aren’t enough to thank everyone who made this moment possible Sharing an ASCO oral with my co-mentor David Braun and other giants in the field during intern year was surreal Grateful for my Dana-Farber Lank Center for Genitourinary Oncology family, the 💩team, and the one and only Toni Choueiri, MD More

After an injury sidelined his 8th PMC, Toni Choueiri, MD is showing us what it means to commit as a Reimagined Rider. He may be off the road, but he’s still driving impact—supporting Dana-Farber and riding with heart and determination. hubs.ly/Q03v3Mjz0

🚀 4pm at #KCRS25: Rapid Oral Session w Sumanta K. Pal, MD, FASCO Featuring: ▪️ Tom Powles Q-TWiST ▪️ koral shah, md FKSI-23 ▪️ Chad Tang, MD MRWS ▪️ Carolina Alves Costa Silva, MD, PhD Microbiome ▪️ Ruchi Agarwal Global disparities ▪️ #JJones WIRE ▪️ Miguel Zugman Papillary RCC Don’t blink. This one’s fast-paced & packed!

We’re just one day away from the 7th Annual Kidney Cancer Research Summit! We can’t wait to talk about innovation, access, and the science that will shape the future of #KidneyCancer care. #KCRS25 #AcceleratingCures

Rock the Run 2025 secure.qgiv.com/event/rockther…

Thank you KidneyCAN for this opportunity

#KCRS25 Rapid Abstract: Carolina Alves Costa Silva, MD, PhD @gustaveroussy will explore MAdCAM-1, a gut biomarker tied to poor outcomes in RCC and a potential guide for microbiota-focused therapies. Read the abstracts: bit.ly/AbstractsKCRS25 Register: bit.ly/RegisterKCRS25 #AcceleratingCures

Hi again! 👋🏻 My name is Juan, I’m a PGY-3 at Yale applying to cardiology. Interested in HF, global health, and med ed. Excited to connect with future colleagues and mentors! #CardiologyFellowship 🫀 Yale IM Traditional Residency Program Yale Internal Medicine Mark D. Siegel Yale Cardiology

Go MZ go

Microbiome expert Carolina Alves Costa Silva, MD, PhD elegantly presentsthe data on MAdCAM-1 in association with outcomes to IO-based therapies Circulating MadCAM-1 is a promising baseline and dynamic biomarker I love our 💩team! Marc Machaalani, MD #KCRS25 OncoAlert

#KCRS25 Session 4 featured rapid-fire insights from researchers around the globe, highlighting early data and fresh perspectives that may shape the next wave of kidney cancer research. Quality of Life in Belzutifan vs. Everolimus with Tom Powles Patient Experience Across the

One of the reasons I love KidneyCAN's #KCRS25: Hearing luminaries in the field of #kidneycancer present their take on data hot off the press. So cool to see Toni Choueiri, MD Robert Motzer MD Naomi Haas #McDermott sharing a stage & offering perspective on the latest from ASCO, ESMO - Eur. Oncology &

What an incredible slide from Wenxin (Vincent) Xu at #KCRS2025 depicting some of the individuals that have contributed to biomarker research in RCC 🔬. “Biomarkers are a lot of work, but they will reduce both overtreatment and undertreatment” KidneyCAN OncoAlert

🚨Internal medicine applicant Marc Machaalani, MD presents the work on KIM-1 like a pro⭐️ KIM-1 is a promising biomarker as well as a great reflection of broader tumor biology #KCRS25 OncoAlert